Sigrid Lundberg

The MEST score provides earlier risk prediction in lgA nephropathy

Sean J. Barbour, Gabriela Espino-Hernández, Heather N. Reich et al. · Kidney International · 2015 · 289 citations · Full text

Medicine, Internal Medicine, Nephrology +10

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy

Krzysztof Kiryluk, Elena Sánchez, Francesca Zanoni et al. · Nature Genetics · 2023 · 172 citations · Full text

Life Sciences, Bioinformatics, Nephrology +17

Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study

Simon Jarrick, Sigrid Lundberg, Adina Welander et al. · Journal of the American Society of Nephrology · 2019 · 165 citations · Full text

Medicine, Immunology, Nephrology +16

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update

Rosanna Coppo, Graziella D’Arrigo, Giovanni Tripepi et al. · Nephrology Dialysis Transplantation · 2018 · 111 citations · Full text

Medicine, Nephrology, Pathology +17